BioVie Inc. (BIVI)

[ejobkar]

Feb 6th Press Release:

“We are pleased to have achieved this important clinical milestone as we continue to develop BIV201 for patients with refractory ascites who are at high risk of deadly complications,” stated BioVie Chief Medical Officer Patrick Yeramian, MD. “What we have learned from this initial study is informing our next clinical trial design. The results will be presented to the FDA in the first half of 2019 and we expect to receive guidance on the BIV201 clinical development plan.”

https://irdirect.net/prviewer/release/id/3609971